Core Viewpoint - Baihe Co., Ltd. has reported an increase in shareholder accounts and a slight decrease in average shareholding quantity, indicating a growing interest among retail investors despite a minor decline in average shareholding value [1][2]. Group 1: Shareholder Statistics - As of June 30, 2025, the number of shareholders for Baihe Co., Ltd. reached 8,574, an increase of 459 accounts or 5.66% from March 31, 2025 [1][2]. - The average number of shares held per account decreased from 7,887 shares to 7,464 shares during the same period [1][2]. - The average market value of shares held per account was 314,500 yuan, which is higher than the industry average of 262,300 yuan [1][2]. Group 2: Stock Performance - From March 31, 2025, to June 30, 2025, Baihe Co., Ltd. experienced a stock price increase of 5.43% [1][2]. - During this period, the company saw a net outflow of 27.02 million yuan from institutional investors and a net inflow of 31.49 million yuan from retail investors [2]. - The stock was listed on the "Dragon and Tiger List" twice during this period, with institutional special seats also appearing twice [2].

Group 1 - The board of directors of Weihai Bihua Biotechnology Co., Ltd. held its 13th meeting on August 29, 2025, with all 9 directors present, confirming compliance with relevant laws and regulations [1] - The board approved the 2025 semi-annual report and its summary with a unanimous vote of 9 in favor [2] - The board also approved a special report on the storage and actual use of raised funds for the first half of 2025, again with a unanimous vote of 9 in favor [2] Group 2 - The board resolved to cancel the supervisory board and amend the company’s articles of association, transferring the supervisory functions to the audit committee of the board, with a unanimous vote of 9 in favor [3] - The board approved the revision and establishment of internal governance systems to enhance management and governance structure, with a unanimous vote of 9 in favor [3] - The board proposed to hold the first extraordinary general meeting of shareholders in 2025 on September 26, 2025, to review the resolutions submitted by the board [3]

Group 1 - The Supervisory Board of Weihai Bihua Biotechnology Co., Ltd. held its 11th meeting of the 4th session on August 29, 2025, with all 3 attending supervisors present, confirming compliance with relevant laws and regulations [1][2] - The Supervisory Board approved the company's 2025 semi-annual report and its summary, with a unanimous vote of 3 in favor and no opposition or abstentions, affirming the report's authenticity and completeness [2] - The Supervisory Board also approved the special report on the storage and actual use of the raised funds for the first half of 2025, with the same voting results, confirming compliance with regulatory requirements and the absence of any violations [2]

Core Viewpoint - The report highlights the performance and strategic direction of Weihai Baihe Biotechnology Co., Ltd. for the first half of 2025, emphasizing the company's resilience in a transforming industry and its focus on innovation and product diversification to meet evolving consumer needs [1][9]. Company Overview and Financial Indicators - The company reported a revenue of 420.35 million yuan for the first half of 2025, a 2.06% increase compared to the same period last year [3]. - The total profit for the period was 82.36 million yuan, reflecting a decrease of 13.38% year-on-year [3]. - The net profit attributable to shareholders was 71.88 million yuan, down 13.37% from the previous year [3]. - The net assets attributable to shareholders increased by 4.28% to 1.67 billion yuan [3]. Industry Situation and Main Business - The industry is experiencing continuous expansion and structural upgrades, with a notable demand for high-end functional products driven by consumer upgrades [6]. - The company specializes in the research, production, and sales of nutritional health foods, offering a wide range of products including soft capsules, hard capsules, tablets, powders, and bottled drinks [6][9]. - The company has established a comprehensive product matrix that covers various health needs across different consumer demographics, including families, infants, and the elderly [9][14]. Business Model - The company operates under two main sales models: contract manufacturing and proprietary brands, with a focus on providing full-process services from product development to production [7][8]. - The contract manufacturing model serves domestic and international brand operators, while the proprietary brand model includes brands like "Baihe Kang" and "Hongyang Shen" [7][8]. - The company employs a "make-to-stock" and "make-to-order" production strategy to optimize production efficiency and meet customer demands [6][8]. Competitive Advantages - The company has developed a forward-looking R&D system and a responsive market capability, allowing it to capture diverse consumer health needs effectively [11]. - It has established a comprehensive quality control system that spans the entire production process, ensuring compliance with international standards [13]. - The company is committed to innovation in product development, focusing on clean label standards and differentiating its products in the market [9][14].

Company Overview - Weihai Baihe Biotechnology Co., Ltd. reported total assets of approximately 1.87 billion RMB at the end of the reporting period, reflecting a 3.07% increase compared to the previous year [1] - The company's operating income for the reporting period was approximately 420.35 million RMB, which is a 2.06% increase from 411.88 million RMB in the same period last year [1] - The total profit for the period was approximately 82.36 million RMB, showing a decrease of 13.38% compared to 95.08 million RMB in the previous year [1] - The net profit attributable to shareholders of the listed company was approximately 69.64 million RMB, down 13.68% from 80.67 million RMB in the same period last year [1] Shareholder Information - The largest shareholder, Liu Xinli, holds 40.94% of the shares, amounting to 26,198,803 shares [2] - Other significant shareholders include Liu Zhaomin with 3.03% (1,936,742 shares) and Liu Luzeng with 2.67% (1,710,730 shares) [2] - Liu Zhaomin is identified as the actual controller of the company, and there are familial connections among the major shareholders [2]

Group 1 - The core point of the article is that Baihe Co., Ltd. announced the convening of its fourth board meeting on August 29, 2025, to review the semi-annual report for 2025 [1] - For the year 2024, Baihe Co., Ltd.'s revenue composition shows that nutritional health products account for 99.27% of total revenue, while other businesses contribute 0.73% [1] - As of the report, Baihe Co., Ltd. has a market capitalization of 2.7 billion yuan [1] Group 2 - The article also mentions the upcoming A-class car exhibition in Southwest China, highlighting the competitive landscape with nearly 120 brands and 1,600 vehicles participating [1] - The event is expected to reshape the market dynamics for new energy vehicles [1]

证券代码：603102 证券简称：百合股份 公告编号：2025-036 威海百合生物技术股份有限公司 关于取消监事会并修订公司章程及修订公司治理制度的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 威海百合生物技术股份有限公司（以下简称"公司"）于 2025 年 8 月 29 日召开第四届董事会第十三次会议，审议通过了《关于取消监事会及修订公司章 程的议案》及《关于修订及制定公司内部治理制度的议案》，现将相关事宜公告 如下。 一、公司章程修订情况 根据《中华人民共和国公司法》的最新规定，公司将不再设监事会，监事会 的职权由董事会审计委员会行使。在此背景下，公司对《威海百合生物技术股份 有限公司章程》（以下简称"公司章程"）进行全面修订。此次修订涉及公司章 程全篇，为突出本次修订的重点，本公告仅就重要条款的修订对比作出展示，其 余只涉及部分文字表述的调整内容将不再逐一比对。具体修订内容如下： | 修订前条款 | 修订后条款 | | --- | --- | | 董事长为公司的法定代表人。 | 第八条 董事长为公司的法定代表 ...

证券代码：603102 证券简称：百合股份 公告编号：2025-034 威海百合生物技术股份有限公司 关于公司 2025 年半年度募集资金存放与实际使用情况 的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）扣除发行费用后的实际募集资金金额、资金到账时间 （一）募集资金管理制度情况 为了规范募集资金的管理和使用，保护投资者权益，公司已按《上市公司监 管指引第 2 号—上市公司募集资金管理和使用的监管要求》等相关文件的规定， 结合公司实际情况，制定了《威海百合生物技术股份有限公司募集资金使用管理 制度》（以下简称"《管理制度》"），对募集资金实行专户存储制度，对募集资 金的存放、使用、项目实施管理、投资项目的变更及使用情况的监督等进行了规 定，公司按照《管理制度》的规定管理募集资金，专户存放、专款专用、严格管 1 理、如实披露。 （二）募集资金监管协议情况 2022 年 1 月，公司与中国农业银行股份有限公司威海龙须岛支行（以下简 称"农业银行威海龙须岛支行"）、青岛银行股份有限公司威海分行 ...

证券代码：603102 证券简称：百合股份 公告编号：2025-035 股东大会召开日期：2025年9月26日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 威海百合生物技术股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 26 日 14 点 00 分 召开地点：山东省威海市荣成市荣义路 2899 号公司研发大楼四楼会议室 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 26 日 至2025 年 9 月 26 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东 ...

证券代码：603102 证券简称：百合股份 公告编号：2025-033 威海百合生物技术股份有限公司 第四届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 威海百合生物技术股份有限公司（以下简称"公司"）于 2025 年 8 月 18 日 向各位监事发出了召开第四届监事会第十一次会议的通知。2025 年 8 月 29 日， 第四届监事会第十一次会议以现场表决方式在公司会议室召开，应出席本次会议 的监事 3 人，实际出席本次会议的监事 3 人，监事会主席刘禄增先生主持会议， 会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的 有关规定。 （一）审议通过了《关于公司 2025 年半年度报告及其摘要的议案》 表决结果：3 票同意，0 票反对，0 票弃权。 监事会认为，董事会编制和审核 2025 年半年度报告及其摘要的程序符合法 律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上市公 司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 （二 ...